FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019557023> ?p ?o ?g. }

• W2019557023 endingPage "14" @default.
• W2019557023 startingPage "9" @default.
• W2019557023 abstract "SUMMARY Gastro‐oesophageal reflux disease (GERD) occurs in up to 44% of adults in the USA. Most individuals do not seek medical help, self‐medicating with antacids. Manifestations of GERD range from symptoms without oesophagitis, which constitute the bulk of patients who self‐medicate, to active oesophagitis and then to complications such as stricture and ulceration. It is the more severe cases who tend to come to the gastroenterologist, but it must be remembered that reflux symptoms are probably around 5–10 times more common than actual oesophagitis. Since acid in the refluxate is responsible for the bulk of the symptoms and mucosal damage, antacids are often used for quick relief—which of course may not be sustained. More prolonged suppression of acid secretion, such as by a histamine H 2 ‐receptor antagonist (H 2 RA) or a proton pump inhibitor (PPI), is required to give long‐lasting symptomatic relief and heal any inflammatory change. H 2 ‐receptor antagonists inhibit acid secretion with an effect that lasts for 4–8 h with a single dose, decreasing stimulated acid secretion by around 70%. When treating oesophagitis, the H 2 RAs suffer from the disadvantage of their relatively short duration of action (compared with PPIs), development of tolerance, and incomplete inhibition of acid secretion in response to a meal. Therefore, it is not easy for the H 2 RAs to achieve optimum conditions for healing the more severe forms of oesophagitis—even very high doses may fail. In mild GERD the H 2 RAs have been shown to be effective in relieving symptoms. In particular, when there is no oesophagitis, relief of reflux symptoms has been obtained after 4 weeks in almost all cases with a twice daily regimen: and it would seem that the sensitivity of the oesophageal mucosa may be reduced so that symptomatic remission is often obtained for a prolonged period after stopping therapy. In the milder forms of oesophagitis (grades I or II) healing can be achieved with all the H 2 RAs in 40–60% of cases in 8 weeks. This can be increased, by a substantial increase in dosage, to around 50–70%, but seldom higher than that. This higher dose has cost and compliance considerations. Proton pump inhibitors are required for higher percentage healing and especially for more severe disease." @default.
• W2019557023 created "2016-06-24" @default.
• W2019557023 creator A5016939586 @default.
• W2019557023 date "1995-04-01" @default.
• W2019557023 modified "2023-10-17" @default.
• W2019557023 title "The role and limitations of H2-receptor antagonist in the treatment of gastro-oesophageal refrux disease" @default.
• W2019557023 cites W1530382242 @default.
• W2019557023 cites W1652224009 @default.
• W2019557023 cites W1658956668 @default.
• W2019557023 cites W175535849 @default.
• W2019557023 cites W1979463242 @default.
• W2019557023 cites W1985499927 @default.
• W2019557023 cites W2000391993 @default.
• W2019557023 cites W2008846484 @default.
• W2019557023 cites W2016891497 @default.
• W2019557023 cites W2020008501 @default.
• W2019557023 cites W2021800274 @default.
• W2019557023 cites W2023928645 @default.
• W2019557023 cites W2025836248 @default.
• W2019557023 cites W2026804251 @default.
• W2019557023 cites W2027233630 @default.
• W2019557023 cites W2027852470 @default.
• W2019557023 cites W2033340618 @default.
• W2019557023 cites W2035793994 @default.
• W2019557023 cites W2049629310 @default.
• W2019557023 cites W2082065898 @default.
• W2019557023 cites W2093226163 @default.
• W2019557023 cites W2112543433 @default.
• W2019557023 cites W2114865489 @default.
• W2019557023 cites W2118898409 @default.
• W2019557023 cites W2140773443 @default.
• W2019557023 cites W2152611772 @default.
• W2019557023 cites W2166090512 @default.
• W2019557023 doi "https://doi.org/10.1111/j.1365-2036.1995.tb00778.x" @default.
• W2019557023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7495945" @default.
• W2019557023 hasPublicationYear "1995" @default.
• W2019557023 type Work @default.
• W2019557023 sameAs 2019557023 @default.
• W2019557023 citedByCount "61" @default.
• W2019557023 countsByYear W20195570232012 @default.
• W2019557023 countsByYear W20195570232014 @default.
• W2019557023 countsByYear W20195570232016 @default.
• W2019557023 countsByYear W20195570232017 @default.
• W2019557023 countsByYear W20195570232018 @default.
• W2019557023 countsByYear W20195570232019 @default.
• W2019557023 countsByYear W20195570232020 @default.
• W2019557023 countsByYear W20195570232021 @default.
• W2019557023 countsByYear W20195570232022 @default.
• W2019557023 crossrefType "journal-article" @default.
• W2019557023 hasAuthorship W2019557023A5016939586 @default.
• W2019557023 hasConcept C1122143 @default.
• W2019557023 hasConcept C126322002 @default.
• W2019557023 hasConcept C170493617 @default.
• W2019557023 hasConcept C22130703 @default.
• W2019557023 hasConcept C2776885963 @default.
• W2019557023 hasConcept C2777014526 @default.
• W2019557023 hasConcept C2777498785 @default.
• W2019557023 hasConcept C2777504413 @default.
• W2019557023 hasConcept C2779134260 @default.
• W2019557023 hasConcept C2779422922 @default.
• W2019557023 hasConcept C2779920096 @default.
• W2019557023 hasConcept C2781025758 @default.
• W2019557023 hasConcept C43270747 @default.
• W2019557023 hasConcept C49039625 @default.
• W2019557023 hasConcept C71924100 @default.
• W2019557023 hasConcept C90924648 @default.
• W2019557023 hasConceptScore W2019557023C1122143 @default.
• W2019557023 hasConceptScore W2019557023C126322002 @default.
• W2019557023 hasConceptScore W2019557023C170493617 @default.
• W2019557023 hasConceptScore W2019557023C22130703 @default.
• W2019557023 hasConceptScore W2019557023C2776885963 @default.
• W2019557023 hasConceptScore W2019557023C2777014526 @default.
• W2019557023 hasConceptScore W2019557023C2777498785 @default.
• W2019557023 hasConceptScore W2019557023C2777504413 @default.
• W2019557023 hasConceptScore W2019557023C2779134260 @default.
• W2019557023 hasConceptScore W2019557023C2779422922 @default.
• W2019557023 hasConceptScore W2019557023C2779920096 @default.
• W2019557023 hasConceptScore W2019557023C2781025758 @default.
• W2019557023 hasConceptScore W2019557023C43270747 @default.
• W2019557023 hasConceptScore W2019557023C49039625 @default.
• W2019557023 hasConceptScore W2019557023C71924100 @default.
• W2019557023 hasConceptScore W2019557023C90924648 @default.
• W2019557023 hasIssue "s1" @default.
• W2019557023 hasLocation W20195570231 @default.
• W2019557023 hasLocation W20195570232 @default.
• W2019557023 hasOpenAccess W2019557023 @default.
• W2019557023 hasPrimaryLocation W20195570231 @default.
• W2019557023 hasRelatedWork W1972259282 @default.
• W2019557023 hasRelatedWork W1990872639 @default.
• W2019557023 hasRelatedWork W2052569066 @default.
• W2019557023 hasRelatedWork W2069405925 @default.
• W2019557023 hasRelatedWork W2157908996 @default.
• W2019557023 hasRelatedWork W2159905106 @default.
• W2019557023 hasRelatedWork W2394944086 @default.
• W2019557023 hasRelatedWork W2463900517 @default.
• W2019557023 hasRelatedWork W3141404013 @default.
• W2019557023 hasRelatedWork W3142083002 @default.
• W2019557023 hasVolume "9" @default.

• next